Eratrectinib

Eratrectinib
Clinical data
Other namesVC004
Identifiers
  • (6R)-15-cyclopropyl-9-fluoro-2,11,15,16,20,21,24-heptazapentacyclo[16.5.2.02,6.07,12.021,25]pentacosa-1(24),7(12),8,10,18(25),19,22-heptaen-17-one
CAS Number
PubChem CID
IUPHAR/BPS
UNII
Chemical and physical data
FormulaC21H22FN7O
Molar mass407.453 g·mol−1
3D model (JSmol)
  • C1C[C@@H]2C3=C(CCN(NC(=O)C4=C5N=C(N2C1)C=CN5N=C4)C6CC6)N=CC(=C3)F
  • InChI=InChI=1S/C21H22FN7O/c22-13-10-15-17(23-11-13)5-8-28(14-3-4-14)26-21(30)16-12-24-29-9-6-19(25-20(16)29)27-7-1-2-18(15)27/h6,9-12,14,18H,1-5,7-8H2,(H,26,30)/t18-/m1/s1
  • Key:URXMBXJZRCIDQB-GOSISDBHSA-N

Eratrectinib is an investigational new drug that is being developed by Jiangsu Vcare Pharmatech for the treatment of solid tumors. It is a Trk receptor antagonist targeting specifically TRKA, TRKB and TRKC.

It has been approved in June 2026 for use in treating for solid tumors in China.

References

  1. ↑ "Eratrectinib". AdisInsight. Springer Nature Switzerland AG. Retrieved 3 July 2026.
  2. ↑ Zhou S, Zhang C, Wang G, Qian J, Huang G, Wang J, et al. (June 2026). "Safety, efficacy, and pharmacokinetics of eratrectinib (VC004) in solid tumors with NTRK fusions: phase 1 results from a phase 1/2 study". Experimental Hematology & Oncology. doi:10.1186/s40164-026-00799-9. PMID 42351304.
  3. ↑ "NMPA Approves Vcare's Eratrectinib for NTRK Tumors". AllSci. 5 June 2026.